Log in
TSE:NVC

Neovasc Stock Forecast, Price & News

Add
Today's Range N/A
50-Day Range N/A
52-Week Range N/A
Volume46,869 shs
Average Volume111,876 shs
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A
BetaN/A
Neovasc Inc. (Neovasc) is a specialty medical device company. The Company develops, manufactures and markets products for the cardiovascular marketplace. The Company's segment is the development, manufacture and marketing of medical devices. Its products include the Tiara technology in development for the transcatheter treatment of mitral valve disease, the Neovasc Reducer for the treatment of refractory angina, and tissue products. The Tiara is in preclinical/early clinical stage development to provide a minimally invasive transcatheter device for patients experiencing mitral regurgitation (MR) as a result of mitral heart valve disease. The Reducer is an hourglass-shaped, balloon-expandable, stainless steel, bare metal device, which is implanted in the coronary sinus, creating a restriction in venous outflow from the myocardium (the muscular layer of the heart wall). Neovasc produces Peripatch, a biological tissue product that is manufactured from pericardium.
Read More

Beat the Market (BTM) Rank

Analyst Opinion: 0.0Community Rank: 2.8Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

0.56 out of 5 stars


Industry, Sector and Symbol

Industry N/A
Sub-IndustryN/A
SectorN/A
CUSIPN/A
CIKN/A
Phone+1-604-2704344

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A

Profitability

Miscellaneous

EmployeesN/A
Next Earnings Date11/5/2020 (Estimated)
OptionableNot Optionable
30 days | 90 days | 365 days | Advanced Chart

Receive NVC News and Ratings via Email

Sign-up to receive the latest news and ratings for NVC and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Neovasc (TSE:NVC) Frequently Asked Questions

Do Wall Street analysts recommend investors buy shares of Neovasc?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Neovasc in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Neovasc
.

When is Neovasc's next earnings date?

Neovasc is scheduled to release its next quarterly earnings announcement on Thursday, November 5th 2020.
View our earnings forecast for Neovasc
.

What other stocks do shareholders of Neovasc own?

Who are Neovasc's key executives?

Neovasc's management team includes the following people:
  • Paul L. Geyer, Independent Chairman of the Board
  • Fred Colen, President, Chief Executive Officer
  • Christopher Clark, Chief Financial Officer, Corporate Secretary
  • Brian McPherson, Chief Operating Officer
  • Vicki Lee Bebeau, Vice President - Clinical Affairs
  • Randy Lane, Vice President - Research & Development
  • Alexei J. Marko, Director
  • Jane H. Hsiao Ph.D., Independent Director (Age 69)
  • Douglas Glen Janzen, Independent Director
  • William O'Neill, Independent Director (Age 61)

What is Neovasc's stock symbol?

Neovasc trades on the Toronto Stock Exchange (TSX) under the ticker symbol "NVC."

How do I buy shares of Neovasc?

Shares of NVC and other Canadian stocks can be purchased through online brokerage accounts that support trading on the Toronto Stock Exchange (TSX). Brokers that permit trading on the TSX include Fidelity, Interactive Brokers, PennTrade, and Charles Schwab.

How big of a company is Neovasc?

Neovasc has a market capitalization of C$0.00.

What is Neovasc's official website?

The official website for Neovasc is www.neovasc.com.

How can I contact Neovasc?

Neovasc's mailing address is 13562 Maycrest Way Suite 5138, RICHMOND, BC V6V 2J7, Canada. The company can be reached via phone at +1-604-2704344.

This page was last updated on 9/19/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.